Featured Research

from universities, journals, and other organizations

Lung Treatments For Premature Babies Under Study

Date:
May 8, 2007
Source:
Medical College of Georgia
Summary:
A pig-derived surfactant given to premature babies whose lungs aren't yet making the lubricant reduces mortality rates by 19 percent over two other commercially-available surfactants, researchers say.

Premature lungs don't immediately produce the essential lubricant, and air sacs are quickly damaged trying to function without it, even with ventilator support.
Credit: Image courtesy of Medical College of Georgia

A pig-derived surfactant  given to premature babies whose lungs aren’t yet making the lubricant reduces  mortality rates by 19 percent over two other commercially-available surfactants,  researchers say.

A retrospective study of 24,883  premature babies with respiratory distress syndrome treated in 191 U.S. hospitals from January 2003 to June 2006  showed reduced mortality for all causes in babies given poractant alfa,  according to lead researcher Dr. Jatinder Bhatia, chief of the Section of  Neonatology at the Medical College of Georgia in Augusta. “The differences hold true whether  you are sitting in a rural hospital or teaching hospital or non-teaching  hospital.”

The study was the first to compare  all three natural surfactants used in this country to treat babies with respiratory  distress syndrome. Previous studies, comparing poractant alfa with calf-derived  beractant, have yielded similar results; studies comparing beractant and  calfactant, also calf-derived, demonstrated no differences in mortality. The  smaller studies prompted researchers to do their more comprehensive review.

“We are looking at a large,  vulnerable population and we need this kind of data to make informed decisions,”  Dr. Bhatia says. He notes that the current analysis doesn’t explain differences  in mortality so additional studies might be needed.

   About 12.7 percent of babies are  born prematurely in the United States annually and about 30,000-40,000 babies  have respiratory distress with surfactant deficiency. “It’s inversely related to gestational  age and birth weight: the younger the baby, the higher the percentage of these  babies that have little or no surfactant,” says Dr. Bhatia.

Surfactant is a viscous, soapy-like substance that keeps thousands of air  sacs inside the lungs from sticking together when they inflate and deflate  while breathing.  “If you think of the  lungs as a million little balloons, these balloons collapse when the baby tries  to breathe out and that is why they get into respiratory distress,” says Dr.  Bhatia.

Premature lungs don’t immediately  produce the essential lubricant, and air sacs  are quickly damaged trying to function without  it, even with ventilator support.

Neonatologists try to prevent damage  by giving surfactant within the first hour after birth to tide the baby over  until his own lungs start producing it some 48 hours later, Dr. Bhatia says. Prescribed  surfactant will eventually become part of the baby’s endogenous pool. “We can give surfactant of a similar  composition as Mother Nature would have made to help ameliorate the disease  process. The basic premise is to give surfactant as early as possible to  prevent the baby’s lungs from collapsing. Once they collapse, it takes greater  support from the outside to reopen these units,” Dr. Bhatia says.

The surfactant effect is almost instantaneous. In fact, neonatologists are  increasingly taking babies off the ventilator at the same time surfactant is  given. Prenatal steroids, which accelerate lung maturity, are given to mothers  when premature birth is imminent. Lung-sparing measures, such as the lowest  possible ventilator setting, also are used.

Pig-derived poractant alfa, a relative newcomer approved by the FDA in 1999,  was the least-used surfactant in the study population. Of the 24,883 babies in  the data base provided by Charlotte, N.C.-based Premier Inc. 4,953 got  poractant alfa, marketed as Curosurf®; 12,653 got beractant marketed as  Survanta®; and 7,277 got calfactant, marketed as Infasurf®. Results are being presented May 7 during the Pediatric Academic  Societies Annual Meeting in Toronto.

Co-authors on the study included researchers at Women’s and Children’s  Hospital in Los Angeles and the University of  Oklahoma Health Sciences Center in Oklahoma City.

The study was funded by Dey,  L.P. and Chiesi Farmaceutici of Parma,   Italy, which  market and make poractant alfa. None of the researchers have financial  interests in either company. 


Story Source:

The above story is based on materials provided by Medical College of Georgia. Note: Materials may be edited for content and length.


Cite This Page:

Medical College of Georgia. "Lung Treatments For Premature Babies Under Study." ScienceDaily. ScienceDaily, 8 May 2007. <www.sciencedaily.com/releases/2007/05/070507102011.htm>.
Medical College of Georgia. (2007, May 8). Lung Treatments For Premature Babies Under Study. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2007/05/070507102011.htm
Medical College of Georgia. "Lung Treatments For Premature Babies Under Study." ScienceDaily. www.sciencedaily.com/releases/2007/05/070507102011.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) — The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) — An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) — Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) — Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins